Statistics for Donanemab (LY3002813) Phase 1b Study in Alzheimer’s Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging

Total visits

views
Donanemab (LY3002813) Phase 1b Study in Alzheimer’s Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging 68

Total visits per month

views
August 2024 0
September 2024 0
October 2024 0
November 2024 0
December 2024 0
January 2025 1
February 2025 0

File Visits

views
Lowe2021Donanemab-CCBY.pdf 1490
java.util.UUID:24aa5e61-003d-4683-a331-f7ed2c57c88b 484
java.util.UUID:be25737c-f30e-4f2b-a363-4fa37e978648 17
java.util.UUID:23adb036-2e0b-4de6-b563-88379ed83b8f 14

Top country views

views
United States 58
China 1
India 1
South Korea 1

Top city views

views
Wilmington 42
Ann Arbor 5
Ashburn 1
Baltimore 1
Cambridge 1
Fairfield 1
Houston 1
Hyderabad 1
Lake Mary 1
Mount Laurel 1
Reston 1
Seodaemun-gu 1
Tustin 1
Washington 1